Based on: Psoriasis (Nail / Palmoplantar) — gene targets, candidate compounds and trials, OSMF Research Tracker (DGIdb, Open Targets, ChEMBL, PubMed and ClinicalTrials.gov data). Numbers are a snapshot taken 8 October 2026; the tracker page is the live version.
Short answer: as of October 2026, the OSMF Research Tracker lists 52 candidate interventions for psoriasis (Nail / Palmoplantar) that are either approved medicines or have at least one registered clinical trial, built on 10 druggable gene targets, with 14 recent trials on ClinicalTrials.gov. 10 are already approved medicines, for this condition or another one; where the approval is for a different condition, the trial is testing a new use, which is what drug repurposing means. Being in a trial says an intervention is being studied, not that it works; that is what the trial is for.
Which candidates have the most trial activity?
Ranked by the number of registered trials the tracker found. Each trial ID links to the registry entry, where you can read the design, status and sponsor.
- Methotrexate — 4 registered trials · approved medicine · NCT00932113 NCT03402087 NCT02634801
- Risankizumab — 4 registered trials · approved medicine · NCT04713592 NCT04451720 NCT03675308
- Ustekinumab — 4 registered trials · approved medicine · NCT04761627 NCT01008995
- Deucravacitinib — 3 registered trials · approved medicine · NCT05744466 NCT05124080 NCT07256015
- Guselkumab — 3 registered trials · approved medicine · NCT05049798 NCT04914429 NCT03573323
- Ixekizumab — 3 registered trials · approved medicine · NCT02634801 NCT03573323 NCT02584855
- Secukinumab — 3 registered trials · approved medicine · NCT03384745 NCT03020199 NCT02721966
- BMS-986165 — 3 registered trials · investigational · NCT03402087 NCT02931838 NCT03624127
- UVB phototherapy — 3 registered trials · investigational · NCT00748020 NCT00940862
- Adalimumab — 2 registered trials · approved medicine · NCT04808739 NCT00940862
- Apremilast — 2 registered trials · approved medicine · NCT05744466 NCT03624127
- Bimekizumab — 2 registered trials · approved medicine · NCT07219420 NCT06425549
Which gene targets are these built on?
The tracker starts from genes with evidence of being druggable in psoriasis (Nail / Palmoplantar) and asks which compounds act on them. Each symbol links to its DGIdb entry, which lists the interacting drugs and the papers behind them: IL12B, IL17A, IL17RA, IL1RL2, IL23A, IL36RN, JAK1, PDE4D, TNF, TYK2.
Which trials are registered?
- The Psoriasis, Atherosclerosis, and Cardiometabolic Disease Initiative (PACI) NCT01778569 · Completed · started 2013-01-22
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO NCT03816345 · Recruiting · Phase PHASE1 · started 2019-07-16
- Retinal Capillary Vessel Density and Foveal Avascular Zone Size in Patients With Psoriatic Arthritis: A Case-Control Study. NCT07858591 · Recruiting · Phase NA · started 2026-09-01
- A Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically NCT07654751 · Recruiting · Phase PHASE4 · started 2026-08-07
- Treatment of Psoriasis With Depression and/or Anxiety With Methotrexate vs Combined Methotrexate and Antidepressant NCT07432815 · Completed · Phase PHASE4 · started 2026-02-01
- A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis NCT03987763 · Active Not Recruiting · Phase PHASE4 · started 2019-10-22
- A Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With Psoriasis NCT06952465 · Active Not Recruiting · started 2025-01-24
- A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis NCT07013201 · Recruiting · Phase PHASE2 · started 2025-09-11
- Early Intervention in Plaque Psoriasis: is Bimekizumab Able to Delay Chronic Inflammation? NCT06742333 · Recruiting · Phase PHASE2 · started 2025-07-22
- Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis NCT07039110 · Recruiting · started 2025-09-09
How to read this
Evidence is graded on the tracker page in three tiers: clinical (tested in people), mechanistic (a documented action on the target) and correlative (an association in the literature). Most candidates sit in the lower tiers, and many trials are small or early-phase. The purpose of this list is to show where the research is, with sources, so that patients, clinicians and researchers can look further; it is not a ranking of what to take.
Related on this site
Research information, not medical advice. Decisions about any medicine belong with you and your clinician. The underlying data are open (CC BY 4.0) and refreshed daily; this note was generated from the tracker page on 8 October 2026.